Douglas Roepke

Peptides, proteins and oligonucleotide are becoming essential medical treatments for many progressive, debilitating, or life-threatening diseases. However, the development of these potential therapies can be derailed by product immunogenicity as it can impact on safety and efficacy…

Forum Co-Chairs: Fiona Cornel, _Health Canada, _JR Dobbins, _Eli Lilly and Company,_ Doug Richardson,_ Merck & Company, Inc…